Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.

image shows hand holding a nasal spray which administers the drug.

In the US, patients who start esketamine ($600 a dose) are asked about whether they have previously taken ketamine ($10 a dose), but not the other way round.

Associate Professor Rupert McShane, University of Oxford, says,

"History teaches us just how important it is to track patients who switch from one potentially addictive drug to another. European and UK regulators urgently need to ensure that treatments with ketamine, and other potentially addictive drugs, are all tracked in the same system along with esketamine. This same logic applies to people who are self-treating without a prescription. This sensible precaution would help prevent esketamine from suffering the same fate as benzodiazepines: overuse, backlash and stigma."

 

Patients' experiences matter – this sort of data platform will give them a voice.Associate Professor Rupert McShane.

 

Read the full article authored by Rupert McShane and Adam Winstock.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New Research Presented at the ECNP Conference - October 2021

Dr Angharad de Cates and Dr Liliana Capitão were just two of the department's researchers presenting and publishing new research at the European College of Neuropsychopharmacology (ECNP) Conference 2021, in Lisbon.

Researchers Address Mental Health Effects of the Pandemic on Young People

In a new policy briefing, a team of researchers at King’s College London and Oxford University highlight the multiple effects that the COVID-19 pandemic has had on children and young people in the UK through their education and daily life, including challenges around social isolation, academic pressures, adjusting to online learning and coping with reopening of schools.

Turing Fellowships for Over 30 Oxford Academics

Professor John Geddes, WA Handley-elect Chair of Psychiatry, is one of the thirty-three University of Oxford researchers, which have been named Turing Fellows for the 2021/22 academic year.

Simple Intervention Effectively Treats Depression During COVID 19

New research shows that even a very simple intervention, administered by non-specialists with just 15 hours of training, can effectively treat depression during COVID-19.

Over a Third of COVID-19 Patients Diagnosed with at Least One Long-COVID Symptom

A new study from the University of Oxford and the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC) investigated long-COVID in over 270,000 people recovering from COVID-19 infection, using data from the US-based TriNetX electronic health record network.